 Home > Medical News > Latest Medical News > Samsung Pharmaceuticals and GemVax submit new drug Phase III trial results

Samsung Pharmaceuticals and GemVax submit new drug Phase III trial results

 Last Update: 2021-06-17
 Source: Internet
 Author: User

Tags

3 4 symbol

innate immune cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Samsung Pharmaceutical Co.
, Ltd.
announced today that the company has submitted the results of a Phase III clinical trial of its pancreatic cancer immunotherapy candidate "RIAVAX™ (GV1001)" in South Korea at the 2021 American Society of Clinical Oncology (ASCO) annual meeting
.

"RIAVAX™ (GV1001)" is a peptide drug derived from human telomerase composed of 16 amino acids
.

It is an immunotherapy drug for pancreatic cancer, used to activate immune cells to attack cancer cells

In 16 hospitals in South Korea (including Severance Hospital), the RIAVAX Phase III clinical trial was conducted with gemcitabine/capecitabine to study the safety and efficacy in 148 patients with locally advanced and metastatic pancreatic cancer Sex
.

The results of clinical trials showed that the median overall survival (OS) of the treatment group was 11.
3 months, while that of the control group was 7.
5 months, a statistically significant improvement (p=0.
021)
.

Another key endpoint is the time to tumor progression (TTP), which also showed statistical significance at 7.

Samsung Pharmaceuticals introduced the domestic rights license for RIAVAX™ from its affiliate GemVax & KAEL Co.
, Ltd.
in 2014
.

From 2007 to 2011, GemVax & KAEL conducted a large-scale RIAVAX™ Phase III clinical trial ("TeloVac") in the UK.

Note: The original text has been deleted

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.